


THE VALUE OF THE DENGUE VACCINE NEW PREVENTION TOOL IN THE FIGHT AGAINST A HIGH DISEASE BURDEN

DENGUE IS THE FASTEST-GROWING
INFECTIOUS DISEASE.

Incidence has grown **30X** in 50 years⁽¹⁾

1965 2015



1 / 2 THE WORLD
IS AT RISK OF DENGUE



The estimated number of cases, globally, each year:

500,000 hospitalizations⁽²⁾

96 million symptomatic cases⁽²⁾

Greatest number of cases globally occurs in pre-adolescent to adult populations⁽³⁾



\$9 billion estimated direct and indirect medical costs⁽⁴⁾

Estimated average cost per case in dengue-endemic countries:⁽⁵⁾

\$500 per ambulatory case

\$1500 per hospitalized case



Average number of school or work days missed for someone suffering from dengue.⁽⁵⁾

VACCINE EFFICACY⁽⁶⁾

In clinical trials among at-risk populations of

9

to 16 years old, over a 25-month period:

- 2 out of 3 cases of dengue caused by any of the four types of the virus were prevented
- 8 out of 10 hospitalizations were prevented
- 9 out of 10 severe forms of dengue were prevented

THE POTENTIAL OF A HIGH-IMPACT VACCINATION PROGRAM

Vaccination can help the public health community in dengue-endemic nations tip the balance in favor of dengue control, adding a critical line of defense to comprehensive dengue prevention efforts.



Disease modelling shows that **broad vaccination** amongst ages 9 and older in dengue endemic countries has the potential to reduce the disease burden by **50% over 5 years**⁽⁷⁾

VACCINATION
MOSQUITO CONTROL
DENGUE PREVENTION EDUCATION
COMMUNITY MOBILIZATION
DIAGNOSIS AND CASE MANAGEMENT

The dengue vaccine could serve as a new line of defence to complement prevention efforts by governments, families and individuals in dengue-endemic countries, having a greater impact on the disease burden and helping to get dengue under control. Now, dengue-endemic countries can have a better chance of reaching the WHO objectives for reducing dengue mortality by 50% and morbidity by 25% by 2020.⁽¹⁾

Sources:
1. World Health Organization. Global strategy for dengue prevention control 2012-2020. Geneva: WHO, 2012. Available at: http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034_eng.pdf. Last accessed December 2015
2. World Health Organization. Dengue and severe dengue. Factsheet No 117, updated May 2015. Available at: <http://www.who.int/mediacentre/factsheets/fs117/en/>; Last accessed July 2015
3. Jackson N, et al « Recent scientific and clinical advances in Sanofi Pasteur's Dengue Vaccine Program » ASTMH 64th Annual Meeting October 25-29, 2015, Philadelphia, PA, USA
4. Shepard DS, Halasa YA, Undurraga EA, Stanaway J. Global economic cost of dengue illness. Poster presented at: American Society of Tropical Medicine and Hygiene Annual Meeting; Oct. 25-29, 2015, Philadelphia, PA, Poster 781
5. Suaya, Jose et al. Cost of Dengue Cases in Eight Countries in the Americas and Asia: A Prospective Study. Am. J. Trop. Med. Hyg., 80(5), 2009, pp. 846-855
6. Hadinegoro, Sri Rezeki S., et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease Integrated Analysis of Efficacy and Interim Long-Term Safety Data for a Dengue Vaccine in Endemic Regions. July 27, 2015 DOI: 10.1056/NEJMoa1506223
7. Coudeville L, Baurin N. Potential impact of dengue vaccination: insights from the first large-scale efficacy trials. Poster presented at 64th ASTMH Annual Meeting - October 25-29, 2015, Philadelphia, Pennsylvania, USA. Poster #3234